$DHR

The UN’s 2026 Sustainable Development Goals health report warns healthcare progress may stall as international funding declines. It says only 36% of 139 targets are on track or making moderate progress, while 49% move too slowly and 15% regressed. Separately, Danaher names Julie Sawyer Montgomery CEO in Oct 2026 and reaffirms 2026 guidance; Johnson & Johnson shifts leadership in Innovative Medicine; P&G expands Health Care after buying Thorne for $3.8bn; Heidi reports NHS AI adoption.

Danaher announced its board appointed Julie Sawyer Montgomery as President and CEO effective Oct. 1, 2026, replacing Rainer Blair, who stays as senior advisor until Mar. 31, 2027. The article links the move to her role growing Diagnostics revenue from about $6.0B to $11.0B since 2017 and highlights Danaher’s 2026 Q2 guidance cut and longer-term $31.7B revenue and $6.9B earnings targets for 2029.

Abbott Laboratories (ABT) reported fiscal Q2 2026 results, with sales up 13% reported and 4.8% comparable, GAAP diluted EPS $0.53 and adjusted $1.31, and raised full-year 2026 adjusted EPS guidance to $5.45-$5.60. Danaher (DHR) posted Q2 revenue $6.3B (+5.5% YoY) and adjusted EPS $1.94 vs $1.83 estimates, but cut full-year core revenue outlook upper end to 4% from 6%.

Danaher (DHR) reported Q2 results July 21, beating earnings estimates and raising adjusted EPS guidance. The company said Life Sciences trends improved, but bioprocessing revenue was weaker and it cut the upper end of full-year core revenue growth to 4% from 6%. Q2 revenue rose 5.5% to $6.3B; adjusted EPS guidance was lifted to $8.45-$8.60.

Danaher said its board selected Julie Sawyer Montgomery as President and CEO effective Oct 1, 2026. According to the company, she helped grow its Diagnostics platform revenue to about $11B from about $6B and tripled operating profit. Danaher also said Q3 and full-year 2026 guidance is unchanged and outgoing CEO Rainer Blair stays as senior advisor through Mar 31, 2027.

Danaher (NYSE:DHR) said its board appointed Julie Sawyer Montgomery as President and CEO effective Oct. 1, 2026, with Rainer Blair retiring that day and advising until Mar. 31, 2027. The company cited Diagnostics revenue rising from about $6.0B in 2017 to about $11.0B today and tripled operating profit, plus acquisitions of Masimo and pending StatLab. 2026 guidance unchanged.

DANAHER CORP /DE/ (DHR) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. EX-10.2 3 d161342dex102.htm EX-10.2 EX-10.2 Exhibit 10.2 FINAL VERSION AMENDED AND RESTATED DANAHER CORPORATION OMNIBUS INCENTIVE PLAN LONG-TERM GROWTH AWARD OPTION AGREEMENT Unless otherwise defined herein, the terms defined in the Amended and Restated Danaher Corporation Omnibu

Danaher (NYSE:DHR) shares rose about 2% after hours after the company named Julie Sawyer Montgomery as President and CEO effective Oct. 1, 2026, succeeding Rainer Blair. Danaher also reaffirmed its previously issued Q3 and full-year 2026 guidance. Montgomery led the Diagnostics platform, growing revenue from about $6B in 2017 to about $11B.

Johnson & Johnson (JNJ) reported fiscal Q2 2026 sales up nearly 7% to $25.31B and adjusted EPS of $2.90, above estimates, and raised guidance toward 2026 annual revenue of over $100B. Danaher (DHR) posted Q2 results with improving core growth but weaker-than-expected biotech revenue and a cut in full-year core growth outlook to 3% to 4%.

JPMorgan says investors are overlooking U.S. healthcare stocks and expects sector net income to rise 22% in 2027 after a 1% decline in 2026. The bank cites favorable valuations and predicted earnings growth as a key driver for S&P 500 profits. It names Eli Lilly (LLY), Gilead (GILD), AbbVie (ABBV), Danaher (DHR), and Thermo Fisher (TMO) as top picks, noting risks like a 2028 patent cliff.